One significant advancement in endometrial cancer treatment is the combination of lenvatinib, a targeted therapy, with pembrolizumab, an immunotherapy. A recent phase 3 trial demonstrated that ...

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU ...

Researchers identified a 15-year shift toward surgical de-escalation in gynecologic oncology, marked by fewer surgical ...

As January, a month dedicated to cervical cancer, winds down, an expert talks about how motherhood can still be a possibility ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...